# UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D. C. 20549

# FORM 10-QSB

[ x ]Quarterly report under
Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended
September 30, 2005 or

[   ] Transition report under Section
13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______
to ______

1-9731
(Commission file No.)

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.(Exact name of small
business issuer as specified in its charter)

|DELAWARE                                                       | 72-0925679                          
|-------------------------------------------------------------- | ------------------------------------
|(State or other jurisdiction of incorporation or organization) | (I.R.S. employer identification no.)

25 Sawyer Passway
Fitchburg, Massachusetts 01420(Address of principal executive offices)

(978) 345-5000(Issuers
telephone number, including area code)

Check whether the issuer (1) filed
all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the
past 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
X  No____.

Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ___  No X

As of October 31, 2005 there were
2,666,194 shares of the Companys common stock outstanding.

Transitional Small Business Disclosure Format    
Yes      No X

---

# ARRHYTHMIA RESEARCH
TECHNOLOGY, INC.

TABLE OF CONTENTS

FORM 10-QSB

September 30, 2005

PART I - FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements
        Consolidated Balance Sheets
        Consolidated Statements of Income
        Consolidated Statements of Cash Flows
        Notes to the Consolidated Financial Statements
    Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
    Item 3. Controls and Procedures

PART II - OTHER INFORMATION
    Item 6. Exhibits
    SIGNATURES

Exhibit 31.1 - Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002Exhibit 31.2 - Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002Exhibit 32.1 - Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002Exhibit 32.2 - Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002

---

# PART I  FINANCIAL INFORMATION

# Item 1. Consolidated
Financial Statements

ARRHYTHMIA RESEARCH
TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Balance
Sheets

(Unaudited)

|ASSETS                                                    
|----------------------------------------------------------
|                                                          
|Current assets:                                           
|Cash and cash equivalents                                 
|Trade and other accounts receivable, net of allowance for 
|doubtful accounts of $18,594 and $20,724                  
|Inventories, net                                          
|Deposits, prepaid expenses and other current assets       
|                                                          
|Total current assets                                      
|                                                          
|Property and equipment, net of accumulated depreciation of
|$5,893,912 and $5,370,142                                 
|Goodwill                                                  
|Other intangible assets, net                              
|Deferred income taxes, net                                
|Other assets                                              
|                                                          
|Total assets                                              
|                                                          

|LIABILITIES AND SHAREHOLDERS' EQUITY                                    |  |  |   |           
|----------------------------------------------------------------------- |  |  | - | ----------
|Current liabilities:                                                    |  |  |   |           
|Accounts payable                                                        |  |  | $ | 468,055   
|Accrued expenses                                                        |  |  |   | 476,532   
|Acquisition price payable                                               |  |  |   | -         
|                                                                        |  |  |  
|Total current liabilities                                               |  |  |   | 944,587   
|                                                                        |  |  |  
|                                                                       
|Shareholders' equity:                                                   |  | 
|Preferred stock, $1 par value; 2,000,000 shares authorized, none issued |  |  |   | -         
|Common stock, $0.01 par value; 10,000,000 shares authorized,            |  | 
|3,926,491 shares issued                                                 |  |  |   | 39,265    
|Additional paid-in-capital                                              |  |  |   | 9,598,397 
|Common stock held in treasury, 1,260,297 and 1,266,622 shares at cost   |  |  |   | (3,451,120
|Retained earnings                                                       |  |  |   | 5,257,018 
|                                                                        |  |  |  
|Total shareholders' equity                                              |  |  |   | 11,443,560
|                                                                        |  |  |  
|Total liabilities and shareholders' equity                              |  |  | $ | 12,388,147
|                                                                        |  |  |  

The accompanying notes are an integral part of the consolidated financial statements.

---

ARRHYTHMIA RESEARCH
TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Statements
of Income

(Unaudited)

|                                  | Three Months Ended | Nine Months Ended
|--------------------------------- | ------------------ | -----------------
|                                  | September 30,      | September 30,    
|
|Revenue                           |                    |                  
|Cost of sales                     |                    |                  
|                                  |                    |                  
|Gross profit                      |                    |                  
|                                 
|Selling and marketing             |                    |                  
|General and administrative        |                    |                  
|Research and development          |                    |                  
|                                  |                    |                  
|Income from operations            |                    |                  
|                                 
|Other income, net                 |                    |                  
|                                  |                    |                  
|Income before income taxes        |                    |                  
|                                 
|Income tax provision              |                    |                  
|                                  |                    |                  
|Net income                        |                    |                  
|                                  |                    |                  
|Net income per share - basic      |                    |                  
|                                  |                    |                  
|Net income per share - diluted    |                    |                  
|                                  |                    |                  
|Cash dividends declared per share |                    |                  
|                                  |                    |                  
|Weighted average common shares    |                    |                  
|outstanding - basic               |                    |                  
|Weighted average common shares    |                    |                  
|outstanding - diluted             |                    |                  

The accompanying notes are an integral part of the consolidated financial statements.

---

ARRHYTHMIA RESEARCH
TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Statements
of Cash Flows

(Unaudited)

|                                                                                                                                                                                                      | Nine Months Ended
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -----------------
|                                                                                                                                                                                                      | September 30,    
|
|Cash flows from operating activities:                                                                                                                                                                 |                  
|Net income                                                                                                                                                                                            |                  
|Adjustments to reconcile net income to net cash provided by                                                                                                                                           |                  
|operating activities, net of effects of acquisition:                                                                                                                                                  |                  
|Depreciation and amortization                                                                                                                                                                         |                  
|Changes in operating assets and liabilities:                                                                                                                                                          |                  
|Trade and other accounts receivable                                                                                                                                                                   |                  
|Inventories                                                                                                                                                                                           |                  
|Deposits, prepaid expenses and other assets                                                                                                                                                           |                  
|Accounts payable and accrued expenses                                                                                                                                                                 |                  
|                                                                                                                                                                                                      |                  
|Net cash provided by operating activities                                                                                                                                                             |                  
|                                                                                                                                                                                                      |                  
|Cash flows from investing activities:                                                                                                                                                                 |                  
|Capital expenditures, net of disposals                                                                                                                                                                |                  
|Cash paid for acquisitions                                                                                                                                                                            |                  
|                                                                                                                                                                                                      |                  
|Net cash used in investing activities                                                                                                                                                                 |                  
|                                                                                                                                                                                                      |                  
|Cash flows from financing activities:                                                                                                                                                                 |                  
|Cash dividend paid                                                                                                                                                                                    |                  
|Proceeds from the exercise of stock options                                                                                                                                                           |                  
|                                                                                                                                                                                                      |                  
|Net cash used in financing activities                                                                                                                                                                 |                  
|                                                                                                                                                                                                      |                  
|Net decrease in cash and cash equivalents                                                                                                                                                             |                  
|Cash and cash equivalents at beginning of period                                                                                                                                                      |                  
|                                                                                                                                                                                                      |                  
|Cash and cash equivalents at end of period                                                                                                                                                            |                  
|                                                                                                                                                                                                      |                  
|Supplemental Information:
        At September 30, 2005 the Company has $1,257 of dividends payable.
        In 2005, $100,000 worth of treasury stock was issued in connection with the acquisition.

The accompanying notes are an integral part of the consolidated financial statements.

---

Notes to the Consolidated
Financial Statements

1. Basis of Presentation:

The
unaudited interim consolidated financial statements and related notes have been prepared
pursuant to the rules and regulations of the Securities and Exchange Commission.
Accordingly, certain information and footnote disclosures normally included in complete
financial statements prepared in accordance with generally accepted accounting principles
have been omitted pursuant to such rules and regulations. The accompanying unaudited
interim consolidated financial statements and related notes should be read in conjunction
with the consolidated financial statements and notes thereto included in the Arrhythmia
Research Technology, Inc. and its subsidiaries (the Company) Annual Report on Form 10-KSB for the
year ended December 31, 2004.

The
information presented reflects, in the opinion of the management of the Company, all
adjustments necessary for a fair presentation of the financial results for the interim
period presented.

Interim
results are subject to year-end adjustments and audit of year-end results by the
Companys independent registered public accounting firm.

2. Inventories:

|                                            | September 30, |  | December 31,
|------------------------------------------- | ------------- |  | ------------
|Inventories consist of the following as of: | 2005          |  | 2004        
|Raw materials                               |               |  | $           
|Work-in-process                             |               |  |             
|Finished goods                              |               |  |             
|                                            |               |  |             
|Total                                       |               |  | $           
|                                            |               |  |             

3. Stock-Based Compensation:

The
Company accounts for stock options at intrinsic value in accordance with Accounting
Principles Board Opinion No. 25, Accounting for Stock Issued to
Employees(APB 25),and complies with the
disclosure provisions of Statement of Financial Accounting Standards No. 123,
Accounting for Stock-Based Compensation (SFAS 123) and
Statement of Financial Accounting Standards No. 148, Accounting for
Stock-Based Compensation  Transition and Disclosure
(SFAS 148). Had compensation cost for the Companys stock options
been determined based upon the fair value at the grant date for awards under the plans
consistent with the methodology prescribed under SFAS 123, the Companys net
income would have been adjusted to the pro forma amounts indicated below:

|                                               | Three Months ended |   | Nine months ended
|---------------------------------------------- | ------------------ | - | -----------------
|                                               | September 30,      |   | September 30,    
|                                               | 2005               |   | 2004             
|Net income - as reported                       |                    | $ |                  
|Deduct: Total stock-based compensation expense |                    |  
|determined under fair value based method       |                    |   |                  
|                                              
|Net income - pro forma                         |                    | $ |                  
|                                              
|Basic earnings per share:                      |                    |  
|as reported                                    |                    |   | $                
|pro forma                                      |                    |   | $                
|Diluted earnings per share:                    |                    |  
|as reported                                    |                    |   | $                
|pro forma                                      |                    |   | $                

The fair value of each option grant
under SFAS 123 was estimated on the date of grant using the Black-Scholes option pricing
model with the following assumptions used for grants in 2001 and 2003, respectively: (i)
dividend yield of 0% and 0.94%; (ii) beta of 0.80 and 0.31 for 2001 and 2003,
respectively; (iii) risk free interest rates of 3.0% for all periods; and (iv) expected
option terms of 5 years for all periods.

---

4. Recent Accounting Pronouncements:

In
December 2004, the FASB issued SFAS 123R, Share-Based Payment, which establishes standards
for the accounting for transactions in which an entity exchanges its equity instruments
for goods or services. In March 2005, the SEC issued Staff Bulletin No. 107 (SAB
107) regarding its interpretation of SFAS 123R. A key provision of this statement is
the requirement of a public entity to measure the cost of employee services received in
exchange for an award of equity instruments (including stock options) based on the fair
value of the award on the grant date and recognized over the vesting period. As modified,
SFAS 123R will be effective for the Companys fiscal year beginning January 1, 2006.

The
Company expects that the adoption of SFAS 123R will result in stock-based compensation
expense. Had the Company adopted Statement 123R in prior periods, the Company believes the
impact of that standard would have approximated the impact of Statement 123 as described
in the disclosure of pro forma net income and earnings per share in the above table.

In
November 2004, the FASB issued SFAS No. 151, Inventory Costs, An Amendment of ARB No. 43,
Chapter 4. SFAS No. 151 clarifies that abnormal amounts of idle facility expense, freight,
handling costs and wasted materials should be recognized as current period charges in all
circumstances. We are required to adopt SFAS No. 151 on January 1, 2006. The Company does
not expect the adoption of SFAS No. 151 to have a material impact on the financial
statements.

5. Acquisition:

On
May 7, 2004, the Companys wholly-owned subsidiary, Micron Products, Inc., completed
the purchase of substantially all of the operating assets of privately-held Shrewsbury
Molders Inc., formerly known as New England Molders, Inc. (NEMI) of
Shrewsbury, Massachusetts. Micron paid NEMI a total purchase price of $1,546,000,
including $1,146,000 in cash, and $400,000 in ART common stock. The final payment of
$100,000 in ART stock was made in February 2005. A final adjustment to the value of the
intangible assets was made on March 31, 2005. The adjustment increased the goodwill and
decreased the backlog, customer relationship, and non-compete intangible assets by
$46,000. The adjustment resulted in a decrease of amortization expense of $13,500 in the
period ending March 31, 2005. In August, the Company restructured the administration of the
division resulting in a one time charge of $190,000.

Item 2. Managements
Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Any
forward looking statements made herein are based on current expectations of the Company,
involve a number of risks and uncertainties and should not be considered as guarantees of
future performance. The factors that could cause actual results to differ materially
include: interruptions or cancellation of existing contracts, inability to integrate
acquisitions, impact of competitive products and pricing, product demand and market
acceptance risks, the presence of competitors with greater financial resources than the
Company, product development and commercialization risks, and changing economic conditions
in developing countries. More information about factors that potentially could affect the
Companys financial results is included in the Companys filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the
year ended December 31, 2004.

Overview

The
Companys products are primarily devices that aid in the detection and analysis of
cardiac arrhythmias. A patented product of signal-averaging electrocardiographic (SAECG)
software called the Predictor® series is offered for licensing to original
equipment manufacturers. The primary source of revenue relates to the production and sale
of disposable electrode sensors used as a component part in the manufacture of integrated
disposable electrophysiological sensors. These disposable medical devices are used world
wide in the monitoring of electric signals in various medical applications. In an effort
to leverage current skills, the Company has expanded into both high volume precision
injection molding, and that of more diversified custom injection molding. Management is
attempting to further identify complementary and/or synergistic products, technologies and
lines of business in an effort to broaden the Companys offerings.

---

Results of Operations

Revenue
for the nine months ended September 30, 2005 was $9,871,236 versus $8,246,968 for the nine
months ended September 30, 2004, an increase of 19.7%. Microns medical sensors and
snaps contributed $508,672 to the increase in revenue, while the high volume precision
molded products and other miscellaneous sales contributed $563,501 of the $1,624,268 total
increase in revenue. The increase in sensor revenue includes an increase of over $306,000
in silver surcharge billed to our customers. The New England Molders Divisions
(the NEM division) custom molded products contributed an additional $533,298
in revenue for the first nine months of 2005. The remaining $18,797 increase in revenue
came from the attaching machines business, and other ancillary unrelated
manufacturing projects. There were no sales of the Companys signal-averaging ECG
products in 2005. Non-recurring engineering and tooling revenue accounted for over
$475,000 of the revenues in the nine months ended September 30, 2005. Tooling and
engineering revenues typically occur at the beginning of a product life cycle or when a
customer changes their manufacturing source. After the design and manufacture of the
prototype and/or production tooling, the Company should benefit from product sales as it
begins to operate the customer owned tooling.

Revenue from domestic and foreign
sales for the first nine months is as follows:

|              | Nine Months Ending September 30,
|------------- | --------------------------------
|              | 2005                            
|Canada        |                                 
|United States |                                 
|Europe        |                                 
|Pacific Rim   |                                 
|Other         |                                 
|              |                                 
|Total         |                                 
|              |                                 

The
shift in distribution of sales to the domestic market was a result of the NEM
divisions higher percentage of domestic sales, and increases in Micron
Products high volume precision custom molding business. Canadian sales increases are
the result of market share gains with Microns electrophysiological sensor and snap
product line.

Cost
of saleswas 64.8% of revenue for the nine months ended September 30, 2005
compared to 61.5% of revenue for the same period in 2004. The increase in silver cost is
accounted for to over one percentage point of the 3.3% of revenue increase in the cost of
sales. The NEM division sells the production and prototype molding tools that it designs
and qualifies for production of plastic components. These tools have a significantly lower
margin than the product the tool produces. In the first nine months of 2005, the division
sold $369,742 of production and prototype tooling. Material and energy cost increases also
contributed to the increase of cost of sales in the first nine months. Although management
has been successful in stabilizing a portion of the electricity costs by negotiating a
long-term purchase agreement, natural gas and resin costs continue to rise. Management
continues to investigate strategies to increase the overall gross margin without
sacrificing product quality.

Selling
and marketing expense was $392,658 for the nine months
ended September 30, 2005 as compared to $230,564 for the same period in 2004. The
increased expense of $162,094 is attributable to the sales staff added in connection with
the NEM division and increased business development efforts. The selling and marketing
expense was 4% of sales in the nine months ended September 30, 2005 as compared to 3% of
sales for the same period in 2004. The Company expects selling expenses to remain at
relatively constant levels for the remainder of 2005. Selling expense as a percentage of
sales is expected to decrease over the remainder of 2005 as the Company begins to see
positive results from the business development efforts.

General
and administrative expensewas $1,290,345 for the nine months ended
September 30, 2005 as compared to $1,026,667 for the same period in 2004. The increase of
$263,678 in the nine months ended September 30, 2005 includes the administrative costs
associated with the NEM division, and an increase in other miscellaneous corporate
expenses. The increased cost of NEM division involves the one time $190,000 administrative
restructuring charge of the division. The increase in corporate expenses includes a larger than
expected increase to the fees associated with our annual audit. This increase is separate
from the fees associated with the internal control documentation required to comply with
Section 404 of the Sarbanes Oxley Act. Due to the extension of the implementation date
relating to the internal control documentation, costs we expected to be incurred beginning
in the second quarter of 2005 are not expected to be incurred until some time in early
2006.

---

Research
and development expensewas $25,015 for the nine months ended September 30,
2005 as compared to $47,467 for the same period in 2004. The decrease was related to lower
expenditures for ARTs product, Predictor®7. Inasmuch as base
development work on Predictor 7 has been completed, future product development costs are
expected to be related to modifications under specific product order criteria when product
orders are obtained. Other expenses relate to Microns customer specific electrode
sensor research.

Other
income, netwas $12,928 and $16,125 of income for the nine months ended
September 30, 2005 and September 30, 2004, respectively. The majority of other income is
interest income from the Companys cash balance. In 2005, this income is net of a
$5,641 loss on the disposal of non-producing machinery.

Income
taxesas a percent of income before income taxes were 36% and 37% for the
nine months ended September 30, 2005 and September 30, 2004, respectively. Management will
continue to seek to maximize any tax planning opportunities that could effectively reduce
the Companys income tax provision in the future.

Liquidity and Capital Resources

Working
capital was $4,685,277 on September 30, 2005 compared to $3,726,950 at December 31, 2004,
an increase of $958,327. The working capital increase was a result of the increase of
sales contributing to higher accounts receivable, and increased finished goods inventory
to meet future products demands from the Companys customers. The significant
reduction in liabilities from income tax payments related to the prior year and the final
acquisition payment did not affect the final cash balance as collections for the first
nine months ending September 30, 2005 offset this cash requirement. The increased finished
goods inventory is the combination of NEM production awaiting shipment, and additional inventory requirements for
Micron's products. Capital investment could decrease
working capital further with any significant investment resulting from another
acquisition, significant expansion of production capacity, a medical study, or further
software development.

Net
capital expenditures were $530,544 for the first nine months of 2005 as compared to
$938,339 for the same period in 2004. Capital expenditures in the first nine months of
2005 included $160,000 of continued renovations of 45,000 square feet of space, a portion
of which is occupied by the NEM division. The remaining capital expenditures included
$350,000 for additional machinery and equipment, including $28,000 in deposits and future
obligations for new machinery and tooling.

The
Companys $650,000 stock buyback program announced in June of 2003 has not resulted
in any stock repurchases in the nine months of 2004, or the first nine months of 2005.

The
Company has an unsecured $1,000,000 credit line with a large multinational bank. No funds
have been drawn down on the line as of September 30, 2005.

A
cash dividend of $0.06 per share was announced in the third quarter of 2005. A dividend
totaling $159,972 was paid in September 2005 to shareholders of record on September 13,
2005.

The
Company expects to meet cash demands for its operations at current levels with current
operating cash flows for the foreseeable future.

Critical Accounting Policies

The
preparation of financial statements and related disclosures in conformity with generally
accepted accounting principles requires management to make judgments, assumptions and
estimates that affect the amounts reported. Certain of these significant accounting
policies are considered to be critical accounting policies, as defined below.

A
critical accounting policy is defined as one that is both material to the presentation of
the Companys financial statements and requires management to make difficult,
subjective, and complex judgments that could have a material effect on the Companys
financial condition and results of operations. Specifically, critical accounting estimates
have the following attributes: 1) the Company is required to make assumptions about
matters that are highly uncertain at the time of the estimate; and 2) different estimates
the Company could reasonably have used, or changes in the estimate that are reasonably
likely to occur, would have a material effect on the Companys financial condition or
results of operations.

Estimates
and assumptions about future events and their effects cannot be determined with certainty.
The Company bases its estimates on historical experience and on various other assumptions
believed to be applicable and reasonable under the circumstances. These estimates may
change as new events occur, as additional information is obtained and as the
Companys operating environment changes. These changes have historically been minor
and have been included in the consolidated financial statements as soon as they became
known. In addition, management is periodically faced with uncertainties, the outcomes of
which are not within its control and will not be known for prolonged periods of time.
These uncertainties are discussed in the section above entitled Forward-looking
Statements. Based on a critical assessment of its accounting policies and the
underlying judgments and uncertainties affecting the application of those policies,
management believes that the Companys consolidated financial statements are fairly
stated in accordance with generally accepted accounting principles, and present a
meaningful presentation of the Companys financial condition and results of
operations.

---

Management
believes that the following are critical accounting policies:

Revenue
Recognition and Accounts Receivable

Revenues
from the sale of products are recorded when the product is shipped, title and risk of loss
have transferred to the purchaser, payment terms are fixed or determinable and payment is
reasonably assured.

The
financing of customer purchased tooling utilizes the direct financing method of revenue
recognition. This requires the gain or loss on the sale of the tooling to be recorded at
the time the tool is put into service while the expected payments are reflected as a lease
receivable.

Based
on managements on-going analysis of accounts receivable balances, and after the
initial recognition of the revenue, if an event occurs which may adversely affect the
ultimate collectibility of the related receivable, management will record an allowance for
the bad debt. Bad debts have not had a significant impact on the Companys financial
condition, results of operations or cash flows.

Inventory
and Inventory Reserves

The
Company values its inventory at the lower of cost or market. The Company reviews its
inventory for quantities in excess of production requirements, obsolescence and for
compliance with internal quality specifications. Any adjustments to inventory would be
equal to the difference between the cost of inventory and the estimated net market value
based upon assumptions about future demand, market conditions and expected cost to
distribute those products to market. If actual market conditions are less favorable than
those projected by management, additional inventory reserves may be required.

The
Company maintains a reserve for excess, slow moving, and obsolete inventory as well as
inventory with a carrying value in excess of its net realizable value. A review of
inventory on hand is made at least annually and a provision for excess, slow moving, and
obsolete inventory is recorded. The review is based on several factors including a current
assessment of future product demand, historical experience, and product expiration.

Deferred
Tax Assets

The
Company assesses its deferred tax assets based upon a more likely than not to be realized
criteria. The Company considers future taxable income and ongoing prudent and feasible tax
planning strategies in assessing the need for the valuation allowance.

Asset
Impairment  Goodwill

The
Company reviews the valuation of goodwill and intangible assets to assess potential
impairments on an annual basis. The management evaluates the carrying value of goodwill
and other intangible assets in accordance with the guidelines set forth in SFAS 142. The
value assigned to intangible assets is determined by a valuation based on estimates and
judgment regarding expectations for the success and life cycle of products acquired. To
test for impairment, present values of an estimate of future discounted cash flows related
to the intangible assets are calculated compared to the value of the intangible asset.
Impairment may have a material adverse effect on the Companys financial condition or
results of operations. There was no impairment as of September 30, 2005.

Asset
Impairment  Long Lived Assets

The
Company assesses the impairment of long-lived assets whenever events or changes in
circumstances indicate that the carrying value may not be fully recoverable. When it is
determined that the carrying value of such assets may not be recoverable, the Company
generally measures any impairment based on projected undiscounted future cash flows
attributed to the asset and its carrying value. If the carrying value exceeds the future
discounted cash flows, an impairment would be recorded.

---

# Item 3. Controls and
Procedures

As
of the end of the period covered by this Quarterly Report, the Companys management,
with the participation of the Companys Chief Executive Officer and Chief Financial
Officer (the Certifying Officers), conducted evaluations of the Companys
disclosure controls and procedures. As defined under Sections 13a  15(e) and 15d
 15(e) of the Securities Exchange Act of 1934, as amended (the Exchange
Act), the term disclosure controls and procedures means controls and
other procedures of an issuer that are designed to ensure that information required to be
disclosed by the issuer in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported, within the time periods specified in the
Commissions rules and forms. Disclosure controls and procedures include without
limitation, controls and procedures designed to ensure that information required to be
disclosed by an issuer in the reports that it files or submits under the Exchange Act is
accumulated and communicated to the issuers management, included the Certifying
Officers, to allow timely decisions regarding required disclosures. Based on this
evaluation, the Certifying Officers have concluded that the Companys disclosure
controls and procedures were effective to ensure that material information is recorded,
processed, summarized and reported by management of the Company on a timely basis in order
to comply with the Companys disclosure obligations under the Exchange Act and the
rules and regulations promulgated thereunder.

Further,
there were no changes in the Companys internal control over financial reporting
during the Companys third fiscal quarter that materially affected, or are reasonably
likely to materially affect, the Companys internal control over financial reporting.

---

# PART II  OTHER
INFORMATION

# Item 6. Exhibits

| | (a) | Exhibits |                                                                                                                                   
| | --- | -------- | ----------------------------------------------------------------------------------------------------------------------------------
| |     | 3.0      | Articles of Incorporation(a)                                                                                                      
| |     | 3.1      | By-laws(b)                                                                                                                        
| |     | 10.40*   | Employment agreement between James E. Rouse and the Company
        dated October 5th, 2001(c)                                    
| |     | 10.41    | Asset Purchase Agreement, dated May 7, 2004, between Micron
        Products, Inc. and Shrewsbury Molders, Inc.(d)                
| |     | 31.1     | Certification of the CEO pursuant to Rule 13a-14(a) or Rule
        15(d)-14(a) on page X-1.                                      
| |     | 31.2     | Certification of the CFO pursuant to Rule 13a-14(a) or Rule
        15(d)-14(a) on page X-2.                                      
| |     | 32.1     | Certification pursuant to 18 U.S.C.§1350 as adopted
        pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 on page X-3.
| |     | 32.2     | Certification pursuant to 18 U.S.C.§1350 as adopted
        pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 on page X-4.

| | *Indicates a management contract or compensatory
        plan required to be filed as an exhibit
| | ------------------------------------------------------------------------------------------------
| | (a)                                                                                             
| | (b)                                                                                             
| | (c)                                                                                             
| | (d)                                                                                             

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

| | ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
| | ------------------------------------
|
| | By:                                 
| |                                     
| |                                     
| |                                     
|
| | By:                                 
| |                                     
| |                                     
| |                                     

November 14, 2005